Hematologic Malignancies Clinical Trials

22 studies are recruiting for hematologic malignancies in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

   Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant. Objective: This study is being done …

   Stage

   Phase 1

   Ages

   12 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05470491 on ClinicalTrials.gov

2. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Cancer Center at UMC North ( Site 0018), Tucson, Arizona

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

3. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

   A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   22 in total

   Run by

   Incyte Corporation

   See if you can join NCT07195916 on ClinicalTrials.gov

4. Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

   This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.

   Stage

   Not phased

   Ages

   18 to 80

   Site

   UW Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07285668 on ClinicalTrials.gov

5. Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

   SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory l…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama

   Locations

   32 in total

   Run by

   Sellas Life Sciences Group

   See if you can join NCT04588922 on ClinicalTrials.gov

6. Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

   The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family caregivers (FCGs).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT07186192 on ClinicalTrials.gov

7. Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

   Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers may be treated and potentially cured in 2 ways: (1) Bone marrow transplant (allogeneic hematopoietic cell transplantation, or alloHCT) gives…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07162038 on ClinicalTrials.gov

8. Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

   The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (M…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Highlands Oncology Group ( Site 2728), Springdale, Arkansas

   Locations

   121 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT04728893 on ClinicalTrials.gov

9. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

   The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06296368 on ClinicalTrials.gov

10. A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

    IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City Of Hope, Duarte, California

    Locations

    24 in total

    Run by

    Immunome, Inc.

    See if you can join NCT06823167 on ClinicalTrials.gov

11. Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

    This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus. Olivia will serve as the primary interface for eConsent and enrollment into the registry. The platform will also help create a …

    Stage

    Not phased

    Ages

    Any age

    Site

    Tempus AI, Chicago, Illinois

    Run by

    Tempus AI

    See if you can join NCT07756034 on ClinicalTrials.gov

12. Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

    Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart. Ob…

    Stage

    Not phased

    Ages

    18 to 110

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT05724121 on ClinicalTrials.gov

13. Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

    The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged >/= 65 years with hematologic malignancies.

    Stage

    Phase 1

    Ages

    65 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Run by

    Ronald Paquette

    See if you can join NCT05849207 on ClinicalTrials.gov

14. PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

    The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    12 in total

    Run by

    Pulmotect, Inc.

    See if you can join NCT06665100 on ClinicalTrials.gov

15. A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

    The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07359859 on ClinicalTrials.gov

16. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage

    Not phased

    Ages

    Any age

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    142 in total

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

17. IVIG for Infection Prevention After CAR-T-Cell Therapy

    This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell the…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Cancer Center, Duarte, California

    Locations

    7 in total

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT05952804 on ClinicalTrials.gov

18. Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

    The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

    Stage

    Phase 2

    Ages

    Up to 60

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06807606 on ClinicalTrials.gov

19. Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

    This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myelo…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Penn State Cancer Institute, Hershey, Pennsylvania

    Run by

    Milton S. Hershey Medical Center

    See if you can join NCT06926595 on ClinicalTrials.gov

20. Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

    To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.

    Stage

    Not phased

    Ages

    Any age

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT02457962 on ClinicalTrials.gov

21. Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

    This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of ev…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University - Feinberg School of Medicine, Chicago, Illinois

    Locations

    4 in total

    Run by

    Acrotech Biopharma Inc.

    See if you can join NCT07036133 on ClinicalTrials.gov

22. Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

    This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06028828 on ClinicalTrials.gov